NUR 631 EXAM 1: ADVANCED
PHARMACOLOGY QUESTIONS AND
ANSWERS 100% VERIFIED BY
EXPERTS. 2026/2027
1. A patient with chronic renal failure requires a drug primarily excreted by the kidneys. If the
drug’s half-life is 6 hours in a healthy individual, how should the dosing be adjusted for this
patient?
A. Decrease the dosing interval to maintain steady state
B. Increase the dose to compensate for slower absorption
C. Decrease the dose and increase the dosing interval
D. No adjustment is necessary for renal excretion
Answer: C
Conceptual Explanation: In renal failure, drug clearance is reduced, leading to a
prolonged half-life. To avoid toxicity, the dose should be decreased and/or the interval
between doses should be increased.
2. Which of the following describes the ‘First-Pass Effect’?
A. The excretion of a drug through the kidneys on the first cycle
B. The initial metabolism of a drug in the liver before it reaches systemic circulation
,C. The binding of a drug to plasma proteins upon entering the bloodstream
D. The rate at which a drug reaches its peak plasma concentration
Answer: B
Conceptual Explanation: The first-pass effect occurs when an oral drug is absorbed from
the GI tract and carried to the liver via the portal vein, where it is metabolized before
reaching the rest of the body.
3. A drug has a Volume of Distribution (Vd) of 500L in a 70kg patient. What does this suggest
about the drug’s distribution?
A. The drug is primarily confined to the plasma
B. The drug is highly bound to albumin
C. The drug is rapidly excreted by the kidneys
D. The drug is widely distributed into tissues or stored in fat
Answer: D
Conceptual Explanation: A Vd larger than the total body water (approx 42L) indicates
that the drug is extensively distributed into tissues or sequestered in body fat, rather than
staying in the plasma.
4. Grapefruit juice is a known inhibitor of the CYP3A4 enzyme. If a patient takes a drug
metabolized by CYP3A4 while drinking grapefruit juice, what is the most likely result?
A. Increased plasma levels and risk of toxicity
, B. Decreased plasma levels and therapeutic failure
C. Accelerated renal excretion of the drug
D. No change in the drug’s pharmacokinetics
Answer: A
Conceptual Explanation: CYP3A4 inhibition reduces the metabolism of the drug, leading
to higher-than-expected plasma concentrations and increased risk of toxicity.
5. Which parameter is the best indicator of a drug’s safety margin?
A. Bioavailability
B. Therapeutic Index
C. Half-life
D. Potency
Answer: B
Conceptual Explanation: The Therapeutic Index (TI) is the ratio of the toxic dose to the
therapeutic dose. A larger TI indicates a safer drug.
6. A competitive antagonist acts by:
A. Permanently binding to the receptor site
B. Binding to an allosteric site to change receptor shape
C. Increasing the number of available receptors
PHARMACOLOGY QUESTIONS AND
ANSWERS 100% VERIFIED BY
EXPERTS. 2026/2027
1. A patient with chronic renal failure requires a drug primarily excreted by the kidneys. If the
drug’s half-life is 6 hours in a healthy individual, how should the dosing be adjusted for this
patient?
A. Decrease the dosing interval to maintain steady state
B. Increase the dose to compensate for slower absorption
C. Decrease the dose and increase the dosing interval
D. No adjustment is necessary for renal excretion
Answer: C
Conceptual Explanation: In renal failure, drug clearance is reduced, leading to a
prolonged half-life. To avoid toxicity, the dose should be decreased and/or the interval
between doses should be increased.
2. Which of the following describes the ‘First-Pass Effect’?
A. The excretion of a drug through the kidneys on the first cycle
B. The initial metabolism of a drug in the liver before it reaches systemic circulation
,C. The binding of a drug to plasma proteins upon entering the bloodstream
D. The rate at which a drug reaches its peak plasma concentration
Answer: B
Conceptual Explanation: The first-pass effect occurs when an oral drug is absorbed from
the GI tract and carried to the liver via the portal vein, where it is metabolized before
reaching the rest of the body.
3. A drug has a Volume of Distribution (Vd) of 500L in a 70kg patient. What does this suggest
about the drug’s distribution?
A. The drug is primarily confined to the plasma
B. The drug is highly bound to albumin
C. The drug is rapidly excreted by the kidneys
D. The drug is widely distributed into tissues or stored in fat
Answer: D
Conceptual Explanation: A Vd larger than the total body water (approx 42L) indicates
that the drug is extensively distributed into tissues or sequestered in body fat, rather than
staying in the plasma.
4. Grapefruit juice is a known inhibitor of the CYP3A4 enzyme. If a patient takes a drug
metabolized by CYP3A4 while drinking grapefruit juice, what is the most likely result?
A. Increased plasma levels and risk of toxicity
, B. Decreased plasma levels and therapeutic failure
C. Accelerated renal excretion of the drug
D. No change in the drug’s pharmacokinetics
Answer: A
Conceptual Explanation: CYP3A4 inhibition reduces the metabolism of the drug, leading
to higher-than-expected plasma concentrations and increased risk of toxicity.
5. Which parameter is the best indicator of a drug’s safety margin?
A. Bioavailability
B. Therapeutic Index
C. Half-life
D. Potency
Answer: B
Conceptual Explanation: The Therapeutic Index (TI) is the ratio of the toxic dose to the
therapeutic dose. A larger TI indicates a safer drug.
6. A competitive antagonist acts by:
A. Permanently binding to the receptor site
B. Binding to an allosteric site to change receptor shape
C. Increasing the number of available receptors
